ClinicalTrials.gg
RecruitingNCT07852988Updated Oct 1, 2026

Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes

A Phase 4 interventional study of Pancreatin and Placebo in Type 2 Diabetes (T2DM), sponsored by Silesian Centre for Heart Diseases. Recruiting at 1 site in Poland. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Silesian Centre for Heart Diseases · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland — 27 open to participants now, 38 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Poland.

Planned enrollment
303rd of 333
100 · median 500
Started
2026
with 22 others
Phase 4
28 of 351
1 open now
Primary completion
2027-12
later than 14 of 37 live
Registered
345th of 351
by date

Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, this one is the 303rd largest by planned enrollment of the 333 interventional ones that give a count, is one of 23 that started in 2026, is one of 28 in phase 4, reaches primary completion later than 14 of the 37 other live ones, and was the 345th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

27 of the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, or all of them as a file.
02

Study summary

Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes. GLP-1 agonists and tirzepatide not only effectively lower blood glucose levels but also promote weight loss-primarily by stimulating the satiety center in the central nervous system - and reduce cardiovascular risk. Evidence suggests that oral pancreatin supplementation also enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. In our study we aim to evaluate the impact of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.

Read the detailed description

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two primary incretin hormones secreted from the small intestine on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells. They play a role in regulation of blood glucose levels, particularly postprandial glycemia. Lipids and carbohydrates are the most potent stimulators of incretin hormone secretion. Pancreatin is a mixture of digestive enzymes naturally produced by the pancreas, which is used as a medication supporting macronutrient digestion, especially in cases of exocrine pancreatic insufficiency. Evidence suggests that oral pancreatin supplementation enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. Based on a randomized, placebo-controlled, double-blind study, we aim to evaluate the effect of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.

We plan to recruit a total of 100 patients with type 2 diabetes treated with oral antihyperglycemic drugs or insulin, either as monotherapy or in combination. Patients will be randomly divided into 2 groups:

  • Group of 50 patients receiving pancreatin 25 000 U with up to 3 main meals daily for 3 months
  • Group of 50 patients receiving placebo with up to 3 main meals daily for 3 months

Baseline assessment:

  • Anthropometric parameters: body weight, height, waist-to-hip ratio, body composition (bioelectrical impedance analysis)
  • Laboratory tests: aspartate aminotransferase, alanine aminotransferase, serum amylase, lipid profile, HbA1c, selected cytokines, average glucose concentration from the last 7 days before study start (glucometer - 4 measurements per day), data from the FreeStyle Libre2 continuous glucose monitoring system (2 weeks prior to study start): assessment of TIR (Time in Range 70-180 mg/dL), glycemic variability coefficient (CV), standard deviation (SD), mean glucose concentration, frequency and severity of hypoglycemia; daily insulin requirements from the last 7 days (for insulin-treated patients)

Assessment after study completion:

  • Anthropometric parameters: body weight, height, waist-to-hip ratio, body composition (bioelectrical impedance analysis)
  • Laboratory tests: aspartate aminotransferase, alanine aminotransferase, serum amylase, lipid profile, HbA1c, selected cytokines, average glucose concentration from the last 7 days before study end (glucometer - 4 measurements per day), data from the FreeStyle Libre 2 continuous glucose monitoring system (last 2 weeks of study): assessment of TIR, CV, SD, mean glucose concentration, frequency and severity of hypoglycemia; daily insulin requirements from the last 7 days (for insulin-treated patients).

Should pancreatin demonstrate a beneficial effect on glycemic homeostasis, these formulations could serve as a valuable adjunctive therapy for type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes (T2DM)

Keywords

  • type 2 diabetes
  • pancreatin
  • glycemic control
  • incretin effect
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes diagnosed for at least 12 months
  • Patients treated with oral antihyperglycemic agents and/or insulin as monotherapy or combination therapy
  • Age between 35 and 75 years
  • : 6.5% - 9.0%

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Use of incretin-based drugs (GLP-1 receptor agonists, dual GIP and GLP-1 receptor agonists, DPP-4 inhibitors) currently or within the last 3 months
  • History of pancreatic surgery
  • History of chronic pancreatitis
  • History of acute pancreatitis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Pancreatin

    Participants receiving pancreatin

    Drug: Pancreatin

  • Placebo comparator
    Control

    Participants receiving placebo

    Drug: Placebo

Interventions

  • DrugPancrelipaseStudies of PancrelipasePancrelipase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pancreatin 25 000 U with each of the 3 main meals daily for 3 months

    Also known as: ActiveLab

  • DrugPlacebo

    Placebo capsule with each of the 3 main meals daily for 3 months

    Also known as: ActivLab Placebo

06

What researchers measure

Primary outcomes

  1. Glycemic control

    HbA1c value

    Time frame: 3 months

  2. Time in range

    Time in range (glucose 70-180 mg/dl)

    Time frame: 3 months

Secondary outcomes

  1. Body weight

    Body weight measurement

    Time frame: 3 months

  2. Lipid profile

    Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglicerides

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, Faculty of Medical Sciences Zabrze
    Zabrze, Silesian Voivodeship 41-800, Poland
    Recruiting
08

References and documents

Publications

  • Perano SJ, Couper JJ, Horowitz M, Martin AJ, Kritas S, Sullivan T, Rayner CK. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial. J Clin Endocrinol Metab. 2014 Jul;99(7):2486-93. doi: 10.1210/jc.2013-4417. Epub 2014 Mar 26. PubMed 24670086 ↗
  • Knop FK, Vilsboll T, Larsen S, Hojberg PV, Volund A, Madsbad S, Holst JJ, Krarup T. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E324-30. doi: 10.1152/ajpendo.00059.2006. Epub 2006 Sep 5. PubMed 16954337 ↗
  • Ebert R, Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia. 1980 Sep;19(3):198-204. doi: 10.1007/BF00275269. PubMed 6997121 ↗

Individual participant data

Plan to share: Yes — Deidentified individual participant data and the study protocol will be made available upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: after publication, till 5 yrs

Access criteria: via email:mwrobel@sum.edu.pl

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 16 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 1, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852988
Lead sponsor
Silesian Centre for Heart Diseases
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Aug 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Marta Wróbel, PhD
Contact
mwrobel@sum.edu.pl
48606873060
Paulina Piekarz-Ząbek, MD
Contact
k_bielawa@poczta.fm
‭+48 604 223 652‬
Marta Wróbel, PhD
principal investigator · Department of Internal Medicine, Diabetology and Cardiometabolic Disorders

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pancrelipase

Start the discussion